CBLI: Summary for Cleveland BioLabs, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 4:00am EST - Canadian Markets open in 5 hours and 30 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cleveland BioLabs, Inc. (CBLI)

On Nov 24: 3.80 USD 0.00 (0.00%)

MORE ON CBLI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cleveland BioLabs, Inc. (NCM:CBLI) Delayed quote data

Last Trade:	3.80 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	3.80
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	13.10

Day's Range:	N/A - N/A
52wk Range:	1.15 - 6.35
Volume:	0
Avg Vol (3m):	138,242
Market Cap:	61.60M
P/E (ttm):	N/A
EPS (ttm):	-1.81
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add CBLI to Portfolio

Download Data

HEADLINES

•	Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502
	Marketwire (Mon, Nov 23)

•	Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
	Marketwire (Wed, Nov 18)

•	CLEVELAND BIOLABS INC Financials
	EDGAR Online Financials (Wed, Nov 18)

•	CLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 12)

•	Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit
	Marketwire (Mon, Nov 2)

•	Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
	Marketwire (Tue, Oct 20)

•	Cleveland BioLabs to Present at 8th Annual BIO Investor Forum
	Marketwire (Mon, Oct 19)

•	Department of Defense Increases Ongoing Contract With Cleveland BioLabs for Developmental Studies Related to Protectan CBLB502
	Marketwire (Tue, Oct 6)

•	Rodman & Renshaw Initiates Analyst Coverage of Cleveland BioLabs
	Marketwire (Mon, Oct 5)

•	Cleveland BioLabs keeps cashing in
	at bizjournals.com (Wed, Sep 30)

More Headlines for CBLI...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

CLEVELAND BIOLABS, INC. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•